Counseling Points - November 2008 - (Page 14)

Counseling Points™ Quality of Life and Treatment Options in Rheumatoid Arthritis Continuing Education Posttest To receive credit, please read the newsletter in its entirety and answer the posttest and program evaluation questions using the answer key on page 15. This entire program is also available at www.counselingpoints.com. Please mail or fax the form to Delaware Media Group, 66 South Maple Ave., Ridgewood, NJ 07450, Fax (201) 612-8282. (If you are completing the posttest online, simply hit the “submit” button.) A certificate from the Infusion Nurses Society will be awarded for a score of 80% (8 correct) or better. A certificate will be mailed within 4 to 6 weeks.There is no charge for CE credit. 1. RA patients with depression have significantly worse disease severity, disability, and pain than those RA patients without depression. A) True B) False 2. Effective ways to improve quality of life in RA include: A) pharmacological treatment & nonpharmacologic interventions B) nutritious diet C) appropriate rest D) all of the above 3. Up to of patients who have had RA less than 2 years have radiographic abnormalities. A) 5% B) 40% C) 93% D) None of the above 4. Without early pharmacological intervention in RA: A) decreased physical function, decreased quality of life, disability, and underemployment can be expected B) risk of comorbidities is significantly increased C) life expectancy is reduced by 5 to 15 years D) all of the above 5. The American College of Rheumatology states that intermediate RA disease duration is considered to be: A) ≥5 months B) 6-24 months C) 25-36 months D) none of the above 6. Select the factor that is NOT indicative of poor RA disease prognosis: A) elevated rheumatoid factor B) cigarette smoking C) male sex D) older age 7. Triple DMARD combinations are recommended for all patients with poor prognostic features of RA and moderate or high levels of disease activity, regardless of disease duration. A) True B) False 8. In early RA, TNF antagonist therapy is appropriate for patients whose disease activity is: A) low B) moderate C) high D) low to moderate 9. Approximately what percentage of patients fail TNF antagonist therapy? A) 10% B) 30% C) 64% D) 80% 10. Rituximab is recommended: A) for all RA patients regardless of disease activity B) for patients with high disease activity, poor prognosis, and inadequate response to methotrexate in combination with DMARDs C) for patients with low or moderate disease activity who have failed methotrexate therapy D) none of the above COUNSELING POINTS™ 14 http://www.counselingpoints.com

Table of Contents Feed for the Digital Edition of Counseling Points - November 2008

Counseling Points - November 2008 Welcome Quality of Life and Treatment Options in Rheumatoid Arthritis Counseling Points

Counseling Points - November 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.